Last 12 months
Inside the activity.
1 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2020 Filed Dec 22, 2020 21:21 UTC Amendment |
ROSENWALD LINDSAY A MDDirector
|
PurchaseCOMMON STOCK | 100,000 | $2.66 | $266,000.00 |
DisclosureSEC source: 0001104659-20-138584 · tm2039180-3_4a.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,436 F3 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on December 14, 2020, was $2.59 to $2.73. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes restricted share units, which vest over various time periods. F4 · balance_after: 1,183 ESPP shares were inadvertently omitted from Dr. Rosenwald's original Form 4 filed on December 15, 2020. Read SEC document |
| December 08, 2020 Filed Apr 16, 2021 20:32 UTC |
Achenbach BrianSVP, Fin. & Corp. Controller
|
SaleCOMMON STOCK | 5,185 | $3.03 | $15,710.55 |
DisclosureSEC source: 0001104659-21-051419 · tm2113178-1_4seq1.xml · nonDerivative · entry 5 Achenbach Brian · CIK 0001760132 · SVP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,476 F5 · kind: 5,185 shares were sold in connection with the vesting of 13,750 shares on December 4, 2020, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Achenbach's tax withholding obligations. Mr. Achenbach had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F7 · price: Represents the weighted average sales price. F8 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| October 21, 2020 Filed Apr 16, 2021 20:32 UTC |
Achenbach BrianSVP, Fin. & Corp. Controller
|
SaleCOMMON STOCK | 3,056 | $2.97 | $9,076.32 |
DisclosureSEC source: 0001104659-21-051419 · tm2113178-1_4seq1.xml · nonDerivative · entry 4 Achenbach Brian · CIK 0001760132 · SVP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,661 F4 · kind: 3,056 shares were sold in connection with the vesting of 9,063 shares on October 10, 2020, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Achenbach's tax withholding obligations. Mr. Achenbach had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F7 · price: Represents the weighted average sales price. F8 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| September 15, 2020 Filed Dec 22, 2020 21:18 UTC |
Litchman Manuel MDDirector · President and CEO
|
GrantCOMMON STOCK | 61,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-138581 · tm2039180-1_4.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,846 F3 · shares: 61,000 shares are restricted share units which vest over various time periods. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| August 31, 2020 Filed Dec 22, 2020 21:21 UTC Amendment |
ROSENWALD LINDSAY A MDDirector
|
GrantCOMMON STOCK | 1,182 | $2.48 | $2,931.36 |
DisclosureSEC source: 0001104659-20-138584 · tm2039180-3_4a.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,436 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on March 1, 2020 and ending on August 31, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on February 28, 2020 (the purchase date of the offering period). F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| August 31, 2020 Filed Dec 22, 2020 21:18 UTC |
Litchman Manuel MDDirector · President and CEO
|
GrantCOMMON STOCK | 5,000 | $2.48 | $12,400.00 |
DisclosureSEC source: 0001104659-20-138581 · tm2039180-1_4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,846 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on March 1, 2020 and ending on August 31, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on February 28, 2020 (the purchase date of the offering period). F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| July 14, 2020 Filed Aug 19, 2020 20:32 UTC |
ROSENWALD LINDSAY A MDDirector
|
GrantCommon Stock | 16,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-096925 · tm2028955d3_4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,423 F1 · balance_after: Includes 100,423 restricted stock units which vest over time. Read SEC document |
| July 14, 2020 Filed Aug 19, 2020 16:33 UTC |
WEISS MICHAEL SDirector
|
GrantCommon Stock | 16,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-096926 · tm2028955d4_4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,423 F1 · balance_after: Includes 50,423 restricted stock units which vest over time. Read SEC document |
| July 14, 2020 Filed Aug 19, 2020 20:32 UTC |
Herskowitz NeilDirector
|
GrantCommon Stock | 16,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-096924 · tm2028955d2_4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,423 F1 · balance_after: 101,423 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| July 14, 2020 Filed Aug 19, 2020 16:33 UTC |
ZELEFSKY MICHAEL JDirector
|
GrantCommon Stock | 16,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-096928 · tm2028955d5_4.xml · nonDerivative · entry 1 ZELEFSKY MICHAEL J · CIK 0001266801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,423 F1 · balance_after: 90,423 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| July 14, 2020 Filed Aug 19, 2020 16:32 UTC |
Chill Adam J.Director
|
GrantCommon Stock | 16,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-096923 · tm2028955d1_4.xml · nonDerivative · entry 1 Chill Adam J. · CIK 0001626451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,423 F1 · balance_after: 93,423 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| July 14, 2020 Filed Dec 22, 2020 21:20 UTC Amendment |
ROSENWALD LINDSAY A MDDirector
|
GrantCOMMON STOCK | 16,611 | $2.48 | $41,195.28 |
DisclosureSEC source: 0001104659-20-138582 · tm2039180-2_4a.xml · nonDerivative · entry 2 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,254 F2 · balance_after: Includes restricted share units, which vest over various time periods. F3 · balance_after: 831 ESPP shares were inadvertently omitted from Dr. Rosenwald's original Form 4 filed on August 19, 2020. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:32 UTC |
Litchman Manuel MDDirector · President and CEO
|
PurchaseCOMMON STOCK | 153,846 | $3.25 | $499,999.50 |
DisclosureSEC source: 0001104659-20-073411 · tm2022538-1_4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 488,846 F1 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| May 22, 2020 Filed Apr 16, 2021 20:32 UTC |
Achenbach BrianSVP, Fin. & Corp. Controller
|
SaleCOMMON STOCK | 880 | $3.04 | $2,675.20 |
DisclosureSEC source: 0001104659-21-051419 · tm2113178-1_4seq1.xml · nonDerivative · entry 3 Achenbach Brian · CIK 0001760132 · SVP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,717 F3 · kind: 880 shares were sold in connection with the vesting of 3,438 shares on March 26, 2020, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Achenbach's tax withholding obligations. Mr. Achenbach had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F7 · price: Represents the weighted average sales price. F8 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| May 22, 2020 Filed Apr 29, 2021 20:31 UTC |
Litchman Manuel MDDirector · President and CEO
|
SaleCOMMON STOCK | 8,348 | $3.04 | $25,377.92 |
DisclosureSEC source: 0001104659-21-057674 · tm2113475d1_4.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 813,035 F2 · kind: 8,348 shares were sold in connection with the vesting of 30,500 shares on April 24, 2020, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Litchman's tax withholding obligations. Mr. Litchman had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F3 · price: Represents the weighted average sales price. F4 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| May 22, 2020 Filed Apr 29, 2021 20:31 UTC |
Litchman Manuel MDDirector · President and CEO
|
SaleCOMMON STOCK | 4,025 | $3.04 | $12,236.00 |
DisclosureSEC source: 0001104659-21-057674 · tm2113475d1_4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 821,383 F1 · kind: 4,025 shares were sold in connection with the vesting of 15,250 shares on March 26, 2020, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Litchman's tax withholding obligations. Mr. Litchman had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F3 · price: Represents the weighted average sales price. F4 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| May 21, 2020 Filed May 22, 2020 23:07 UTC |
Litchman Manuel MDDirector · President and CEO
|
PurchaseCommon Stock | 90,000 | $3.13 | $281,700.00 |
DisclosureSEC source: 0001104659-20-065513 · tm2020825d1_form4.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,000 F1 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| May 14, 2020 Filed May 22, 2020 23:07 UTC |
Litchman Manuel MDDirector · President and CEO
|
PurchaseCommon Stock | 90,000 | $2.79 | $251,100.00 |
DisclosureSEC source: 0001104659-20-065513 · tm2020825d1_form4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 F1 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| March 31, 2020 Filed Apr 16, 2021 20:32 UTC |
Achenbach BrianSVP, Fin. & Corp. Controller
|
SaleCOMMON STOCK | 3,033 | $2.64 | $8,007.12 |
DisclosureSEC source: 0001104659-21-051419 · tm2113178-1_4seq1.xml · nonDerivative · entry 2 Achenbach Brian · CIK 0001760132 · SVP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,597 F2 · kind: 3,033 shares were sold in connection with the vesting of 8,750 shares on March 27, 2020, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Achenbach's tax withholding obligations. Mr. Achenbach had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F7 · price: Represents the weighted average sales price. F8 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| March 26, 2020 Filed Apr 29, 2020 12:48 UTC |
Litchman Manuel MDDirector · President and CEO
|
GrantCommon Stock | 122,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-052884 · tm2018004-2_form4.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 F2 · shares: Each restricted stock unit represents the right to receive one share of Common Stock of Mustang Bio, Inc. F3 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| March 26, 2020 Filed Apr 29, 2020 12:48 UTC |
Achenbach BrianSVP, Fin. & Corp. Controller
|
GrantCommon Stock | 36,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-052883 · tm2018004-1_form4.xml · nonDerivative · entry 2 Achenbach Brian · CIK 0001760132 · SVP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,274 F2 · shares: Each restricted stock unit represents the right to receive one share of Common Stock of Mustang Bio, Inc. F3 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| March 05, 2020 Filed Apr 29, 2020 12:48 UTC |
Litchman Manuel MDDirector · President and CEO
|
GrantCommon Stock | 5,000 | $2.48 | $12,400.00 |
DisclosureSEC source: 0001104659-20-052884 · tm2018004-2_form4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on September 1, 2019 and ending on February 29, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on February 28, 2020 (the last trading day of the offering period). Read SEC document |
| March 05, 2020 Filed Apr 29, 2020 12:48 UTC |
Achenbach BrianSVP, Fin. & Corp. Controller
|
GrantCommon Stock | 524 | $2.48 | $1,299.52 |
DisclosureSEC source: 0001104659-20-052883 · tm2018004-1_form4.xml · nonDerivative · entry 1 Achenbach Brian · CIK 0001760132 · SVP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,024 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on September 1, 2019 and ending on February 29, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on February 28, 2020 (the last trading day of the offering period). F3 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| February 28, 2020 Filed Dec 22, 2020 21:20 UTC Amendment |
ROSENWALD LINDSAY A MDDirector
|
GrantCOMMON STOCK | 831 | $2.48 | $2,060.88 |
DisclosureSEC source: 0001104659-20-138582 · tm2039180-2_4a.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,643 F1 · shares: These shares were acquired under the Mustang Bio, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on September 1, 2019 and ending on February 29, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on February 28, 2020 (the last trading day of the offering period) F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| December 06, 2019 Filed Apr 16, 2021 20:32 UTC |
Achenbach BrianSVP, Fin. & Corp. Controller
|
SaleCOMMON STOCK | 6,144 | $3.69 | $22,671.36 |
DisclosureSEC source: 0001104659-21-051419 · tm2113178-1_4seq1.xml · nonDerivative · entry 1 Achenbach Brian · CIK 0001760132 · SVP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,630 F1 · kind: 6,144 shares were sold in connection with the vesting of 13,750 shares on December 4, 2019, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Achenbach's tax withholding obligations. Mr. Achenbach had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. F7 · price: Represents the weighted average sales price. F8 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| August 28, 2019 Filed Jan 17, 2020 22:42 UTC |
ROSENWALD LINDSAY A MDDirector
|
GrantCommon Stock | 13,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005208 · tm203350d1_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,812 F1 · balance_after: Includes 33,812 restricted stock units which vest over time. Read SEC document |
| August 28, 2019 Filed Jan 17, 2020 17:43 UTC |
WEISS MICHAEL SDirector
|
GrantCommon Stock | 13,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005209 · tm203350d2_form4.xml · nonDerivative · entry 2 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,812 F2 · balance_after: Includes 33,812 restricted stock units which vest over time. Read SEC document |
| August 28, 2019 Filed Jan 17, 2020 22:44 UTC |
Herskowitz NeilDirector
|
GrantCommon Stock | 13,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005211 · tm203350d4_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,812 F1 · balance_after: 83,812 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| August 28, 2019 Filed Jan 17, 2020 17:44 UTC |
Chill Adam J.Director
|
GrantCommon Stock | 13,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005210 · tm203350d3_form4.xml · nonDerivative · entry 1 Chill Adam J. · CIK 0001626451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,812 F1 · balance_after: 73,812 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| April 16, 2019 Filed Jan 17, 2020 22:45 UTC |
Achenbach BrianSVP, Fin. & Corp. Controller
|
GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005212 · tm203350d5_form4.xml · nonDerivative · entry 1 Achenbach Brian · CIK 0001760132 · SVP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 F1 · balance_after: 90,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| December 10, 2018 Filed Dec 18, 2018 21:59 UTC |
Litchman Manuel MDDirector · President and CEO
|
PurchaseCommon Stock | 8,000 | $3.35 | $26,804.80 |
DisclosureSEC source: 0001144204-18-065170 · tv509180_form4.xml · nonDerivative · entry 5 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 20, 2018 was $3.8751 to $3.8951, the range of prices for the purchase transactions on November 21, 2018 was $4.1992 to $4.219, the range of prices for the purchase transactions on November 26, 2018 was $3.8696 to $3.8708 and the range of prices for the purchase transactions on December 10, 2018 was $ 3.34 to $ 3.3532. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 04, 2018 Filed Dec 18, 2018 21:59 UTC |
Litchman Manuel MDDirector · President and CEO
|
PurchaseCommon Stock | 7,500 | $3.60 | $27,000.00 |
DisclosureSEC source: 0001144204-18-065170 · tv509180_form4.xml · nonDerivative · entry 4 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| November 26, 2018 Filed Dec 18, 2018 21:59 UTC |
Litchman Manuel MDDirector · President and CEO
|
PurchaseCommon Stock | 5,000 | $3.87 | $19,353.50 |
DisclosureSEC source: 0001144204-18-065170 · tv509180_form4.xml · nonDerivative · entry 3 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 20, 2018 was $3.8751 to $3.8951, the range of prices for the purchase transactions on November 21, 2018 was $4.1992 to $4.219, the range of prices for the purchase transactions on November 26, 2018 was $3.8696 to $3.8708 and the range of prices for the purchase transactions on December 10, 2018 was $ 3.34 to $ 3.3532. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 23, 2018 Filed Dec 7, 2018 21:44 UTC |
Herskowitz NeilDirector
|
PurchaseCOMMON STOCK | 1,000 | $3.96 | $3,960.00 |
DisclosureSEC source: 0001144204-18-063619 · tv507723_form4.xml · nonDerivative · entry 2 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 F1 · balance_after: 70,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| November 21, 2018 Filed Dec 18, 2018 21:59 UTC |
Litchman Manuel MDDirector · President and CEO
|
PurchaseCommon Stock | 5,000 | $4.21 | $21,048.00 |
DisclosureSEC source: 0001144204-18-065170 · tv509180_form4.xml · nonDerivative · entry 2 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 20, 2018 was $3.8751 to $3.8951, the range of prices for the purchase transactions on November 21, 2018 was $4.1992 to $4.219, the range of prices for the purchase transactions on November 26, 2018 was $3.8696 to $3.8708 and the range of prices for the purchase transactions on December 10, 2018 was $ 3.34 to $ 3.3532. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 20, 2018 Filed Dec 3, 2018 17:47 UTC |
Achenbach BrianVP, Fin. & Corp. Controller
|
PurchaseCOMMON STOCK | 500 | $3.87 | $1,937.10 |
DisclosureSEC source: 0001144204-18-062799 · tv508274_form4.xml · nonDerivative · entry 4 Achenbach Brian · CIK 0001760132 · VP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 F1 · balance_after: 55,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| November 20, 2018 Filed Dec 18, 2018 21:59 UTC |
Litchman Manuel MDDirector · President and CEO
|
PurchaseCommon Stock | 2,500 | $3.89 | $9,720.25 |
DisclosureSEC source: 0001144204-18-065170 · tv509180_form4.xml · nonDerivative · entry 1 Litchman Manuel MD · CIK 0001709485 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 20, 2018 was $3.8751 to $3.8951, the range of prices for the purchase transactions on November 21, 2018 was $4.1992 to $4.219, the range of prices for the purchase transactions on November 26, 2018 was $3.8696 to $3.8708 and the range of prices for the purchase transactions on December 10, 2018 was $ 3.34 to $ 3.3532. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 19, 2018 Filed Dec 3, 2018 17:47 UTC |
Achenbach BrianVP, Fin. & Corp. Controller
|
PurchaseCOMMON STOCK | 1,000 | $4.25 | $4,250.00 |
DisclosureSEC source: 0001144204-18-062799 · tv508274_form4.xml · nonDerivative · entry 3 Achenbach Brian · CIK 0001760132 · VP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 F2 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 16, 2018 was $4.15 to $4.3792, and the range of prices for the purchase transactions on November 19, 2018 was $4.15 to $4.35. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F1 · balance_after: 55,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| November 16, 2018 Filed Dec 3, 2018 17:47 UTC |
Achenbach BrianVP, Fin. & Corp. Controller
|
PurchaseCOMMON STOCK | 1,000 | $4.31 | $4,310.00 |
DisclosureSEC source: 0001144204-18-062799 · tv508274_form4.xml · nonDerivative · entry 2 Achenbach Brian · CIK 0001760132 · VP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 F2 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 16, 2018 was $4.15 to $4.3792, and the range of prices for the purchase transactions on November 19, 2018 was $4.15 to $4.35. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F1 · balance_after: 55,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 06:37 UTC |
Chill Adam J.Director
|
GrantCOMMON STOCK | 1,000 | $4.85 | $4,850.00 |
DisclosureSEC source: 0001144204-18-058924 · tv507044_form4.xml · nonDerivative · entry 3 Chill Adam J. · CIK 0001626451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 F1 · balance_after: 60,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 06:37 UTC |
Chill Adam J.Director
|
GrantCOMMON STOCK | 2,000 | $5.34 | $10,680.00 |
DisclosureSEC source: 0001144204-18-058924 · tv507044_form4.xml · nonDerivative · entry 2 Chill Adam J. · CIK 0001626451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 F1 · balance_after: 60,000 shares are restricted Common Stock which vest over various time periods. F2 · balance_after: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on November 8, 2018, was $4.90 to $6.06. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 01:06 UTC |
ROSENWALD LINDSAY A MDDirector
|
PurchaseCOMMON STOCK | 50,000 | $4.41 | $220,500.00 |
DisclosureSEC source: 0001144204-18-057391 · tv506421_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · balance_after: Includes 20,000 restricted stock units which vest over time. Read SEC document |
| June 14, 2018 Filed Nov 13, 2018 06:37 UTC |
Chill Adam J.Director
|
GrantCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-058924 · tv507044_form4.xml · nonDerivative · entry 1 Chill Adam J. · CIK 0001626451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · balance_after: 60,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| June 14, 2018 Filed Dec 7, 2018 21:44 UTC |
Herskowitz NeilDirector
|
GrantCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-063619 · tv507723_form4.xml · nonDerivative · entry 1 Herskowitz Neil · CIK 0001298246 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · balance_after: 70,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| June 14, 2018 Filed Jan 17, 2020 22:41 UTC Amendment |
ROSENWALD LINDSAY A MDDirector
|
GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005207 · tm203350d6_form4.xml · nonDerivative · entry 1 ROSENWALD LINDSAY A MD · CIK 0000941841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: 10,000 restricted stock units were inadvertently omitted from Dr. Rosenwald's original Form 4 filed on 11/05/2018. F2 · balance_after: Includes 20,000 restricted stock units which vest over time. Read SEC document |
| June 14, 2018 Filed Jan 17, 2020 17:43 UTC |
WEISS MICHAEL SDirector
|
GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-005209 · tm203350d2_form4.xml · nonDerivative · entry 1 WEISS MICHAEL S · CIK 0001038977 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · balance_after: Includes 20,000 restricted stock units which vest over time. Read SEC document |
| February 02, 2018 Filed Dec 3, 2018 17:47 UTC |
Achenbach BrianVP, Fin. & Corp. Controller
|
GrantCOMMON STOCK | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-062799 · tv508274_form4.xml · nonDerivative · entry 1 Achenbach Brian · CIK 0001760132 · VP, Fin. & Corp. Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · balance_after: 55,000 shares are restricted Common Stock which vest over various time periods. Read SEC document |
| March 31, 2017 Filed Jun 7, 2017 21:43 UTC |
Fortress Biotech, Inc.10% owner
|
GrantCommon Stock, $0.0001 par value | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 8 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,132,653 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| March 13, 2017 Filed Jun 7, 2017 21:43 UTC |
Fortress Biotech, Inc.10% owner
|
GrantCommon Stock, $0.0001 par value | 767,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 7 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,131,053 F2 · kind: The Reporting Person is entitled to an annual dividend on its outstanding Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on March 13. These shares were granted by the Issuer to the Reporting Person for the 2017 annual dividend. Read SEC document |
| January 31, 2017 Filed Jun 7, 2017 21:43 UTC |
Fortress Biotech, Inc.10% owner
|
GrantCommon Stock, $0.0001 par value | 213,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 6 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,363,789 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.